Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Product › Details

SHS VI fund

Products Next higher product group fund, human health_oo
Period Status 2022-07-18 existent
  Annual sales USD 220,000,000 (fund size at first closing (2022) 2022)
  Document for annual sales SHS Gesellschaft für Beteiligungsmanagement mbH. (7/18/22). "Press Release: More than 220 Million Euros for Growth and Succession Investments in European Healthcare Companies".
Organisation Organisation SHS VI fund
  Group SHS Capital (Group)
     

SHS Gesellschaft für Beteiligungsmanagement mbH. (7/18/22). "Press Release: More than 220 Million Euros for Growth and Succession Investments in European Healthcare Companies".

SHS launches sixth fund generation and exceeds target volume already in first closing


SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over 220 million euros for its sixth fund at the first closing. Faster than expected, the Tübingen-based healthcare investor has already exceeded its target of 200 million euros at the first closing. The sixth SHS fund generation also aims at majority and minority investments in the healthcare sector. A total of 12-15 investments are planned. Investors can still participate in SHS VI until the final closing.

Within the framework of the placement of the sixth fund generation, the investor base was further internationalised. More than half of the SHS VI investors have already participated in predecessor funds, and some of them have also significantly increased their subscription to the new fund generation. SHS attributes the strong demand to its unique selling proposition as a sector specialist and the successful transactions of the last fund generations.

“We would like to thank our investors for their trust,” says Hubertus Leonhardt, SHS partner and managing director responsible for fundraising. “With our sixth fund generation, we are once again offering access to private equity in the growing healthcare market. For our investors, in addition to fund performance, our sector expertise as well as access to transactions is particularly decisive. Furthermore, our ESG and investor relations expertise as well as the offer of co-investment opportunities are also relevant for many of our clients. We are very pleased to have been able to further internationalise our investor base with the sixth fund generation and to expand it with very renowned addresses.”

More than 60 investors are already invested in the SHS VI Fund. These investors come from the areas of funds-of-funds, insurance companies, pension funds, foundations, family offices, banks, healthcare groups, church investors and entrepreneurs. The largest investors include, for example, the European Investment Fund, the Scandinavian foundation Realdania, the Swiss Helsana HealthInvest, the L-Bank Baden-Württemberg and larger family offices. Furthermore, the SHS investment team itself has invested significantly.


Focus on growth financing and corporate succession

“In our deal flow, we see a large number of fast-growing, young as well as established healthcare companies that are eligible for investment by the new fund. Stricter regulation and a high need for innovation and internationalisation are leading to an increasing demand for capital in the sector. For other companies, it is a matter of a successful handover to the next generation. Here, too, as an experienced partner, we can provide companies with targeted and competent support, both with minority and majority investments,” says Uwe Steinbacher, Managing Partner at SHS.

The fund focuses on corporate transactions of up to € 250 million. The fund can refinance the corresponding equity tranches with up to € 50 million from its own resources. In the case of higher equity requirements, SHS increases the volumes by co-investments from investors invested in the fund or syndicates with cooperating private equity houses. Expansion and innovation financing, succession situations and shareholder changes represent the focus of the investments sought. Majority and minority stakes are possible.

Please note that this is a marketing communication. The information on Fund SHS VI is not directed at US investors.


About SHS Gesellschaft für Beteiligungsmanagement mbH:

SHS is a private equity provider founded in 1993 investing in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Building European Healthcare Champions” is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity investment of the AIFM-registered company is up to EUR 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, launched in 2022, with a volume of more than € 200 million.

Further information at: http://www.shs-capital.eu


Would you like regular updates on SHS? Subscribe to our Newsletter and follow us on LinkedIn

Press contact:

Sarah Stelzer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstraße 12
72072 Tübingen
sas@shs-capital.eu

   
Record changed: 2022-08-30

Advertisement

Picture Berlin Partner Top News New Ariceum Radiopharma Lab 650x200px

More documents for fund, human health_oo


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top